Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving two autologous stem cell transplants (one after the other) may be an effective treatment for Hodgkin's lymphoma.

PURPOSE: This phase II trial is studying how well giving two autologous stem cell transplants works in treating patients with progressive or recurrent Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide; Etoposide; Melphalan

Criteria

DISEASE CHARACTERISTICS:

• Histologically* confirmed Hodgkin's lymphoma meeting ≥ 1 of the following criteria:

• Disease progression during initial first line chemotherapy

• Complete response lasting ≤ 90 days after induction

• Partial response lasting ≤ 90 days after induction

• First recurrence/progression with the duration of initial response ≤ 12 months after completion of chemotherapy NOTE: *There must be unequivocal radiological evidence of recurrent or progressive disease if biopsy was not obtained at time of disease recurrence/progression

• No clonal abnormalities in marrow collection

• Must have bilateral or unilateral bone marrow aspirates and biopsy within 42 days prior to stem cell collection

• Must have adequate sections of original diagnostic specimen available for review

• Needle aspirations or cytologies are not adequate

• No prior lymphoma, myelodysplastic syndromes, or leukemia (even if disease free ≥ 5 years)

• No CNS involvement

PATIENT CHARACTERISTICS:

Performance status

• Karnofsky 50-100%

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Bilirubin ≤ 1.5 times upper limit of normal* (ULN) NOTE: *Unless due to Hodgkin's lymphoma

Renal

• Creatinine clearance ≥ 60 mL/min

• Creatinine ≤ 2.0 times ULN

Cardiovascular

• Ejection fraction ≥ 45% by 2-D echocardiogram

• No significant active cardiac disease

Pulmonary

• Adequate pulmonary function

• DLCO ≥ 45%

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer

• No known HIV or AIDS infection

• No active bacterial, fungal, or viral infection

• No medical condition that would preclude study treatment

PRIOR CONCURRENT THERAPY:

Chemotherapy

• See Disease Characteristics

Surgery

• See Disease Characteristics